Acarix AS (Sweden) Performance
| ACARIX Stock | SEK 0.30 0.01 3.23% |
The firm shows a Beta (market volatility) of -0.69, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Acarix AS are expected to decrease at a much lower rate. During the bear market, Acarix AS is likely to outperform the market. At this point, Acarix AS has a negative expected return of -0.15%. Please make sure to confirm Acarix AS's value at risk, rate of daily change, and the relationship between the total risk alpha and expected short fall , to decide if Acarix AS performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Acarix AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest uncertain performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
| Begin Period Cash Flow | 64.1 M | |
| Total Cashflows From Investing Activities | -43 K |
Acarix |
Acarix AS Relative Risk vs. Return Landscape
If you would invest 36.00 in Acarix AS on September 2, 2024 and sell it today you would lose (6.00) from holding Acarix AS or give up 16.67% of portfolio value over 90 days. Acarix AS is generating negative expected returns and assumes 5.1079% volatility on return distribution over the 90 days horizon. Simply put, 45% of stocks are less volatile than Acarix, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Acarix AS Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Acarix AS's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Acarix AS, and traders can use it to determine the average amount a Acarix AS's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0296
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ACARIX |
Estimated Market Risk
| 5.11 actual daily | 45 55% of assets are more volatile |
Expected Return
| -0.15 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Acarix AS is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Acarix AS by adding Acarix AS to a well-diversified portfolio.
Acarix AS Fundamentals Growth
Acarix Stock prices reflect investors' perceptions of the future prospects and financial health of Acarix AS, and Acarix AS fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Acarix Stock performance.
| Return On Equity | -1.46 | |||
| Return On Asset | -0.8 | |||
| Operating Margin | (13.75) % | |||
| Current Valuation | 51.77 M | |||
| Shares Outstanding | 373.33 M | |||
| Price To Book | 1.63 X | |||
| Price To Sales | 15.38 X | |||
| Revenue | 3.76 M | |||
| EBITDA | (48.28 M) | |||
| Cash And Equivalents | 15.86 M | |||
| Cash Per Share | 2.24 X | |||
| Total Debt | 239 K | |||
| Debt To Equity | 2.30 % | |||
| Book Value Per Share | 0.20 X | |||
| Cash Flow From Operations | (48.01 M) | |||
| Earnings Per Share | (0.31) X | |||
| Total Asset | 118.6 M | |||
About Acarix AS Performance
By analyzing Acarix AS's fundamental ratios, stakeholders can gain valuable insights into Acarix AS's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Acarix AS has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Acarix AS has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Acarix AB , a medical technology company, develops and commercializes diagnostic tests for cardiovascular diseases primarily in Europe, China, and the United States. Acarix AB was founded in 2004 and is based in Malm, Sweden. Acarix AB operates under Medical Devices classification in Sweden and is traded on Stockholm Stock Exchange. It employs 11 people.Things to note about Acarix AS performance evaluation
Checking the ongoing alerts about Acarix AS for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Acarix AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Acarix AS generated a negative expected return over the last 90 days | |
| Acarix AS has high historical volatility and very poor performance | |
| Acarix AS has some characteristics of a very speculative penny stock | |
| Acarix AS has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 3.76 M. Net Loss for the year was (51.73 M) with profit before overhead, payroll, taxes, and interest of 2.82 M. | |
| Acarix AS has accumulated about 15.86 M in cash with (48.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.24, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Acarix AS's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Acarix AS's stock is overvalued or undervalued compared to its peers.
- Examining Acarix AS's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Acarix AS's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Acarix AS's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Acarix AS's stock. These opinions can provide insight into Acarix AS's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Acarix Stock analysis
When running Acarix AS's price analysis, check to measure Acarix AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acarix AS is operating at the current time. Most of Acarix AS's value examination focuses on studying past and present price action to predict the probability of Acarix AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acarix AS's price. Additionally, you may evaluate how the addition of Acarix AS to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world |